Transvaginal Mesh Lawsuit

Different factors can trigger urinary incontinence

According to the Mayo Clinic, urinary incontinence isn’t a disease but a symptom. It can be caused by everyday habits, underlying medical conditions or physical problems.

Available treatment for urinary incontinence includes surgery, medication and physical therapy. But some treatments have proven problematic.

Vaginal mesh implants, marketed for treatment of urinary incontinence and pelvic organ prolapse, have prompted thousands of lawsuits due to their tendency to fail and ...

continue reading...

J&J seeks priority review for new drug

The U.S. Food and Drug Administration intends to give priority review to Johnson & Johnson’s experimental treatment for multidrug-resistant tuberculosis.

According to a story in the Newark Star Ledger, Johnson & Johnson’s Janssen Research & Development unit applied for approval to market bedaquiline, or TMC207, on June 29. The drug would be included in combination therapy for adults with multidrug-resistant tuberculosis lung infections.

Under the FDA’s standard review process, the agency aims ...

continue reading...

Court refuses to throw out J&J fine

According to Bloomberg, a Louisiana appeals court declined to throw out an award of nearly $258 million that Johnson & Johnson must pay to state officials, over illegal marketing of its antipsychotic drug Risperdal.

Jurors in Louisiana found Johnson & Johnson officials violated the state’s Medicaid fraud laws 35,542 times over Risperdal. Lawyers for the state argued that the company defrauded Louisiana’s Medicaid program by wrongfully marketing the drug to doctors ...

continue reading...

Troubled J&J appoints new executive

According to a story in the Boston Globe, Johnson & Johnson has appointed Bayer executive Sandra E. Peterson to oversee the company’s troubled consumer health and manufacturing operations.

The move is an attempt by Alex Gorsky, who became CEO of Johnson & Johnson in April, to address a host of quality, legal and ethical problems involving products and sales practices.

Those problems include what the article characterizes as “an eye-popping series of ...

continue reading...

J&J settles Risperdal lawsuit on first day of trial

On the first day of trial, Johnson & Johnson settled a lawsuit centering on complaints that its antipsychotic drug Risperdal caused a male plaintiff to grow breasts, Bloomberg reports. The terms of the settlement are confidential.

It was the first of about 130 lawsuits alleging that Risperdal caused young males to grow breasts. An additional 290 allege other personal injuries caused by the drug.

A lawyer for the plaintiff claimed he suffered ...

continue reading...

Public demands forced corporate changes

An opinion piece for the Boston Globe points out that public scrutiny and consumer activism is what prompted Johnson & Johnson’s recent decision to phase out questionable chemicals in its full line of products.

The piece applauds that decision, and urges members of the public to keep up that kind of pressure where corporate actions and accountability are concerned.

Johnson & Johnson had already acceded to consumer activists’ demands by saying it ...

continue reading...
Page 16 of 29 «...101415161718...»